Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas

Clinical Endocrinology

Volumn 63, Issue 1, 2005, Pages 26-31

  Biswas, M ^a   Smith, J ^a   Jadon, D ^a   McEwan, P ^a   Rees, D A ^a   Evans, L M ^a   Scanlon, M F ^a   Davies, J S ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; TUMOR GROWTH; TUMOR REGRESSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BROMOCRIPTINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 22044447104     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2005.02293.x     Document Type: Article

References (30)

1. Molitch, M. (2001) Disorders of prolactin secretion. Endocrinology and Metabolism Clinics of North America, 30, 585-610.
2. Bassetti, M., Spada, A., Pezzo, G. & Giannattasio, G. (1984) Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. Journal of Clinical Endocrinology and Metabolism, 58, 268-273.
3. General, M., Uozomi, T., Ohta, M., Akihiro, I., Kajiwara, H. & Mori, S. (1984) Necrotic changes in prolactinomas after long-term administration of bromocriptine. Journal of Clinical Endocrinology and Metabolism, 59, 463-470.
4. Ferrari, C., Paracchi, A., Mattei, A.M., De Vincentiis, S., D'Alberton, A. & Crosignani, P. (1992) Cabergoline in the long-term therapy of hyperprolactinaemic disorders. Acta Endocrinologica, 126, 489-499.
5. Sabuncu, T., Arikan, E., Tasan, E. & Hatemi, H. (2001) Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinaemic patients. International Medicine, 40, 857-861.
6. Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonella, R. & Lombardi, G. (2003) Withdrawal of long-term cabergoline for tumoural and nontumoural hyperprolactinaemia. New England Journal of Medicine, 2003, 2023-2033.
7. Webster, J., Piscitelli, G., Polli, A., Ferrari, C., Ismail, I. & Scanlon, M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhoea. New England Journal of Medicine, 331, 904-909.
8. Nomikos, P., Buchfelder, M. & Fahlbusch, R. (2001) Current management of prolactinomas. Journal of Neuro-Oncology, 54, 139-150.
9. Passos, V.Q., Souza, J.J.S. & Musolino, N.R.C. (2002) Long-term follow-up of prolactinomas, Normoprolactinaemia after bromocriptine withdrawal. Journal of Clinical Endocrinology and Metabolism, 87, 3578-3582.
10. Clayton, R.N. & Wass, J.A.H. (1997) Pituitary tumours: recommendations for service provision and guidelines for management of patients. Journal of the Royal College of Physicians, 31, 628-636.
11. Mehmet, S. & Powrie, J.K. (2003) A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clinical Endocrinology, 58, 111-113.
12. Webster, J. (1999) Clinical management of prolactinomas. Ballière's Clinical Endocrinology and Metabolism, 13, 395-408.
13. Scanlon, M.F., Rodriguez-Arnao, M.D., McGregor, A.M., Weightman, D., Lewis, M., Cook, D.B., Gomez-Pan, A. & Hall, R. (1981) Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas; comparison with other tests of hypothalamicpituitary function. Clinical Endocrinology, 14, 133-143.
14. Massara, F., Cammani, F., Martra, M., Dolfin, G.G., Muller, E.E. & Molinatti, G.M. (1983) Reciprocal patterns of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia. Clinical Endocrinology, 18, 103-110.
15. Faglia, G. (1991) Should dopamine agonist treatment for prolactinomas be life-long? Clinical Endocrinology, 34, 173-174.
16. Zarate, A., Canales, E.S., Cano, C. & Pilonieta, C.J. (1983) Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinologica, 104, 139-142.
17. Johnston, D., Hall, K., Kendall-Taylor, P., Patrick, D., Watson, M. & Cook, D. (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas: studies with high-definition computerised tomography. Lancet, 2, 187-192.
18. Moriondo, P., Travaglini, P., Nissim, M., Conti, A. & Faglia, G. (1985) Bromocriptine treatment of microprolactinomas. Evidence of stable prolactin decrease after drug withdrawal. Journal of Clinical Endocrinology and Metabolism, 60, 764-772.
19. Rasmussen, C., Bergh, T. & Wide, L. (1987) Prolactin secretion and menstrual function after long-term bromocriptine treatment. Fertility and Sterility, 48, 550-554.
20. Wang, C., Lam, K., Ma, J., Chan, T., Liu, M. & Yeung, R. (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clinical Endocrinology, 27, 363-371.
21. Winkelmann, W., Allolio, B., Deuss, U., Heesen, D. & Kaulen, D. (1985) Persisting normoprolactinaemia after withdrawal of bromocriptine long-term in patients with prolactinomas. In: R. Macleod, M. Thorner, U. Scapagnini eds. Prolactin: Basic and Clinical Correlates. Liviana Press, Padova, Italy, 817-822.
22. Van't Verlaat, J. & Croughs, R. (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clinical Endocrinology, 34, 175-178.
23. Tindall, G., Kovacs, K., Horvarth, E. & Thorner, M. (1982) Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural and morphometric study. Journal of Clincal Endocrinology and Metabolism, 55, 1178-1183.
24. Landolt, A.M. & Oswalder, V. (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? Journal of Clinical Endocrinology and Metabolism, 58, 1179-1183.
25. Ho, Y., Smythe, G.A., Compton, P.J. & Lazarus, L. (1985) Long term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinaemia. Australian and New Zealand Journal of Medicine, 15, 213-219.
26. Cunnah, D. & Besser, M. (1991) Management of prolactinomas. Clinical Endocrinology, 34, 231-235.
27. Arafah, B.M. & Nasrallah, M.P. (2001) Pituitary tumours: pathophysiology, clinical manifestations and management. Endocrine-Related Cancer, 8, 287-305.
28. Jeffcoate, W.J., Pound, N., Sturrock, N.D.C. & Lambourne, J. (1996) Long term follow up of patients with hyperprolactinaemia. Clinical Endocrinology, 45, 299-303.
29. Muratori, M., Arosio, M., Gambina, G., Biella, O. & Faglia, G. (1997) Use of cabergoline in the long-term treatment of hyperprolactinaemic and acromegalic patients. Journal of Endocrinological Investigation, 20, 537-546.
30. Biswas, M., Smith, J., Jadon, D., McEwan, P., Rees, D.A., Evans, L.M., Scanlon, M.F. & Davies, J.S. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology, in press.